Year: 2014

(Reuters) – Regeneron Pharmaceuticals Inc cut the top end of its full-year sales forecast for its blockbuster eye drug and reported a lower-than-expected adjusted quarterly profit, citing higher costs. The company’s shares fell 7.6 percent to $365 in premarket trading on Tuesday. Regeneron said it expected full-year 2014 sales of Eylea, its eye injection drug, within a range of $1.7 billion to $1.74 billion. The company, more accustomed to raising its Eylea sales forecasts, cut the range from $1.7 billion to $1.8 billion. …
Go to Source

Ballot measures in Oregon and Alaska would set up a network of regulated pot shops, similar to those already operating in Colorado and Washington state after twin landmark votes in 2012. The referendums come amid rapid shifts in Americans' opinions on marijuana in recent years that have seen efforts to legalize cannabis creep closer toward the mainstream and brought about sweeping pot policy changes in states and cities, where the drug remains illegal under federal law. "Win or lose, we expect to see more support and more dialogue about the issue than ever," said Mason Tvert, a spokesman for the Marijuana Policy Project, which is working on legalization measures in California and other states for 2016.

Go to Source

(Reuters) – Medical equipment maker Becton Dickinson & Co reported better-than-expected profit and revenue, helped by strong sales in its diabetes care and drug-delivery businesses. Becton said it expected adjusted earnings from continuing operations to be between $6.76 and $6.83 per share for the year ending September 2015. Analysts on average were expecting $6.70 per share, according to Thomson Reuters I/B/E/S. …
Go to Source

Here's a rundown on foods where preparation may be the difference … mainly uncooked foods will help you to achieve significant weight loss and …
Go to Source

As the patients' weight loss plan begins to take shape, any underlying health issues will be addressed. Gluten free diet plans will be created and Diet …
Go to Source